Senators slam FDA for pain med approval; Lilly's Lechleiter calls for STEM education;

@FiercePharma: Here's why a crowdfunded HIV vaccine project is drawing criticism from some scientists. More | Follow @FiercePharma

@TracyStaton: Gilead won't make hep C sales projections, but doesn't mind if you do. Provided they're huge. Piece | Follow @TracyStaton

@EricPFierce: CEO Bresch's moves in India give Mylan low-cost production tied to a high-value rep. Report | Follow @EricPFierce

@CarlyHFierce: Shire steers Vyvanse toward binge eating as earnings come up aces. Article | Follow @CarlyHFierce

> The FDA has received a letter from thee top U.S. senators demanding to know why it approved hydrocodone drug Zohydro, which doesn't come with abuse-deterrent protections. Story

> GlaxoSmithKline ($GSK) is partnering with the National Institutes of Health (NIH) on developing a treatment for a rare inflammatory disease as a way to widen its respiratory lead. Story

> Eli Lilly ($LLY) CEO John Lechleiter writes in Forbes that companies need to invest in science, technology, engineering and math (STEM) education programs in U.S. public schools to get the high-tech workforce the U.S. needs. Blog

> Daiichi Sankyo and UMN Pharma have entered a collaborative research agreement for a norovirus vaccine.

Medical Device News

@FierceMedDev: Israel's Lumenis is plowing ahead with a planned $100M IPO--device market wariness be damned. Story | Follow @FierceMedDev

@MarkHFierce: Philips scored a strategically smart remote patent monitoring deal with Boston's Partners Healthcare. Article | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes&Ladders: Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone. Report | Follow @MichaelGFierce

@EmilyWFierce: No love for Aveo and Astellas: Companies 'breakup,' end pact to develop cancer drug. Article | Follow @EmilyWFierce

> By winning New York Dx certification, Ariosa gains a valuable marketing tool. Item

> Medtronic unveils a new treatment for peripheral artery disease in Europe. Story

> Ahead of its acquisition by Smith & Nephew, ArthroCare shows its profit. News

Biotech News

@FierceBiotech: Follow the money: Our John Carroll talks money, geography and biotech. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout. More | Follow @JohnCFierce

@DamianFierce: Astellas finally bails on $AVEO, giving up on the thrice-failed tivozanib. Story | Follow @DamianFierce

@EmilyMFierce: BioLineRx shows effectiveness of leukemia drug in preclinical study. Article via FierceBiotech Research | Follow @EmilyMFierce

> AstraZeneca may have a gout blockbuster on its hands with lesinurad. Story

> GlaxoSmithKline eyes rare disease to widen its respiratory lead. Piece

And Finally... #HealthPolicyValentines is back for the third year in a row. More

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.